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Abstract. Teixobactin is a highly promising antibacterial depsipeptide consisting of four D-amino acids and a rare L-allo-enduracididine 
amino acid. L-allo-enduracididine is reported to be important for the highly potent antibacterial activity of teixobactin. However, it is also a 
key limiting factor in the development of potent teixobactin analogues due to several synthetic challenges such as it is not commercially 
available, requires a multistep synthesis, long and repititive couplings (16-30 hours). Due to all these challenges, the total synthesis of 
teixobactin is laborious and low yielding (3.3%). In this work, we have identified a unique design and developed a rapid synthesis (10 min 
µwave assisted coupling per amino acid, 30 min cyclisation) of several highly potent analogues of teixobactin with yields of 10-24% by 
replacing the L-allo-enduracididine with commercially available non-polar residues such as leucine and isoleucine. Most importantly, the 
Leu10-teixobactin and Ile10-teixobactin analogues have shown highly potent antibacterial activity against a broader panel of MRSA and 
Enterococcus faecalis (VRE). Time-kill kinetics data indicate that both these compounds are superior to vancomycin against MRSA (16 
times more potent). Furthermore, these synthetic analogues displayed identical antibacterial activity to natural teixobactin (MIC 0.25 µg/ml) 
against MRSA ATCC 33591 despite their simpler design and ease of synthesis. Detailed NMR analyses have provided us with further 
insight into the 3D structures of these important analogues. We have confirmed lipid II binding and measured the binding affinities of 
individual amino acid residues of Ala10-teixobactin towards geranyl pyrophosphate (a lipid II mimic) by NMR to understand the nature and 
strength of binding interactions of the amino acid residues. An antagonization assay further confirms a lipid II mediated mode of action. 
Contrary to current understanding, we have shown that a cationic amino acid at position 10 is not essential for target (lipid II) binding and 
potent antibacterial activity of teixobactin. We thus provide strong evidence contrary to the many assumptions made about the mechanism of 
action of this exciting new antibiotic. Introduction of a non-cationic residue at position 10 allows for tremendous diversification in terms of 
the design and synthesis of highly potent teixobactin analogues and lays the foundations for the development of teixobactin analogues as 
new drug-like molecules to target MRSA and Mycobacterium tuberculosis. 
Introduction 
 
By 2050, antimicrobial resistance (AMR) is predicted to 
cause more mortality than cancer.1 To address the 
challenges of AMR, there is a continual need to develop 
new antibacterial compounds. The recently discovered 
molecule teixobactin is one such very promising 
antibacterial.2 Teixobactin kills bacteria such as 
Methicillin-resistant Staphylococcus aureus (MRSA) 
and Mycobacterium tuberculosis without detectable 
resistance.2 In 2015, Mycobacterium tuberculosis 
infected 10.4 million individuals and was responsible 
for 1.5 million deaths worldwide.3 Teixobactin kills 
bacteria through the inhibition of cell wall synthesis.2 
The development of resistance against teixobactin is 
predicted to be low because it targets cell wall 
substrates from multiple biosynthetic pathways.4 
Teixobactin, thus, does not target enzymes, but multiple 
bactoprenol-coupled cell wall building blocks such as 
lipid II (needed for peptidoglycan synthesis) and lipid 
III (a starting material for cell wall teichoic acid 
synthesis) leading to inhibition of cell wall synthesis.5  
The targeting of building blocks (lipid II and lipid III) 
rather than enzymes makes it inherently more difficult 
for bacteria to develop resistance. The inhibition of cell 
wall synthesis via multiple pathways results in cell wall 
damage, lysis (due to delocalisation of autolysins, lytic 
enzymes) and cell death. The aforementioned reasons 
make teixobactin an outstanding molecule for antibiotic 
development.6 
 
Teixobactin is an undecapeptide containing four D 
amino acids namely N-Me-D-Phe1, D-Gln4, D-allo-Ile5 
and D-Thr8 (Figure 1, marked in red) and the rare L-
allo-enduracididine amino acid7 (Figure 1A, marked in 
blue). In the past year, articles have been published 
which describe the total synthesis of teixobactin,8 9 and 
the syntheses and biological activities of teixobactin 
analogues10 11 12.  The synthesis of Arg10-teixobactin 
analogues was reported by us11 and others.10 12  Arg10-
teixobactin was obtained by replacing the L-allo-
enduracididine amino acid at position 10 with the 
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 Figure 1. Structure of A. Teixobactin (16) and B. Leu10-Teixobactin (13) with the D amino acids highlighted in red and the L-allo-End and replaced L-Leu 
residue highlighted in blue. MRSA ATCC 33591, Staphylococcus aureus ATCC 29213. 
structurally similar, commercially available arginine. 
Arg10-teixobactin showed a similar trend in terms of 
antibacterial activity as teixobactin. Our previous 
work13 established the importance of D amino acids via 
the total syntheses and biological evaluation of the D 
and L analogues of Arg10-teixobactin. Changing the 
amino acid configuration of any one of the four D 
amino acids (N-Me-D-Phe1, D-Gln4, D-allo-Ile5 and D-
Thr8) from D to L leads to significant loss in 
antibacterial activity. This work also defined the 3D 
molecular structure of seven teixobactin analogues 
whereby (1) the disordered structure of these analogues 
were found to be vital for biological activity, (2) D-Gln4 
is essential and (3) D-allo-Ile5 is important to maintain 
the disordered structure.13 
 
Nowick et al.12 reported a minimum pharmacophore of 
teixobactin coined lipobactin by replacing the N-
terminal residues 1-5 with a dodecanoyl chain. They 
described that any change to D-Thr8 or modification of 
configuration of any of the residues in the core ring 
structure of teixobactin results in a significant decrease 
in activity. The enantiomeric Arg10-teixobactin reported 
by them shows similar biological activity as Arg10-
teixobactin. These results suggest that, in order to 
maintain biological activity, only the relative 
configurations of amino acids are important and not 
their absolute configurations. Very recently, Nowick et 
al. also reported the X-ray crystallographic structure of 
a teixobactin analogue and described its hydrophobic 
interactions, as well as a hydrogen bonding cavity 
featuring a chloride ion.14 The Albericio group has 
reported a lysine scan of  Arg10-teixobactin15. They 
concluded that the replacement of any one of the four 
isoleucine residues with lysine led to complete loss of 
activity. However, replacement of the polar, non-
charged residues Ser3, Gln4 and non-polar alanine by 
lysine resulted in analogues with comparable biological 
activities to that of Arg10-teixobactin. Wu C. et al. have 
reported that the guanidine of arginine or amine of 
lysine at position 10, Ser7 and the NH group of N 
terminal phenylalanine are all critical for the biological 
activity of teixobactin analogues.16 The replacement of 
the arginine or lysine at position 10 by histidine, Ser7 by 
alanine (including analogue 7) and N-methyl 
phenylalanine1 by N,N-dimethyl phenylalanine leads to 
less active teixobactin analogues compared to the Arg10-
teixobactin. Recently, we have reported the synthesis of 
teixobactin analogues by replacing L-allo-
enduracididine with isosteres such as homoarginine10-
teixobactin, norarginine10-teixobactin. These analogues 
showed promising activity against MRSA. However 
these were less active than natural teixobactin.17 
 
In this work, we describe a unique design and rapid 
synthesis of several highly potent analogues of 
teixobactin against Staphylococcus aureus (MSSA), 
Methicillin-resistant Staphylococcus aureus (MRSA) 
and Enterococcus faecalis (Vancomycin-resistant 
Enterococcus, VRE) by replacing the synthetically 
challenging L-allo-enduracididine with commercially 
available non-polar residues such as alanine, leucine 
and isoleucine. This study aims to answer two important 
questions. Firstly, is it essential to incorporate a residue 
with a positively charged side chain at position 10 for 
maintaining target binding (lipid II) and biological 
activity of teixobactin and its analogues? Secondly, 
what are the key residues involved and what are the 
target binding contributions of the individual amino acid 
residues in the teixobactin analogues? To evaluate both 
these questions and identify the key residues 
particularly with respect to position 10, an alanine scan 
was performed on Arg10-teixobactin (Figure 2, 1-8). The 
alanine scanning technique has been used earlier on 
other antimicrobial peptides with success18 but has not 
yet been performed on teixobactin or its analogues. In 
order to further improve the antibacterial activity of 
Arg10-teixobactin by modifying the amino acid at 
position 10, new analogues of teixobactin were prepared 
by systematic replacement of Arg10 with D-Ala (D-
Ala10-teixobactin, 9), Gly (Gly10-teixobactin, 10), Val 
(Val10-teixobactin 11), Ile (Ile10-teixobactin, 12), Leu 
(Leu10-teixobactin, 13), Ser (Ser10-teixobactin, 14) and 
Phe (Phe10-teixobactin, 15) (Figure 2, 9-15). We thus 
synthesised 15 analogues (Figure 2) of teixobactin using 
the conditions described in Figure 3, page S3. 
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Results and Discussion 
Design and Syntheses. In our ongoing research to 
develop potent teixobactin analogues against resistant 
bacteria, we are particularly interested in understanding 
the role of polar amino acid residues at position 10, 
namely; L-allo-enduracididine, arginine and lysine. L-
allo-enduracididine is important for the biological 
activity of teixobactin and its replacement by Arg 
results in decreased biological activity (Table 1). 
However, it is also a key limiting factor in the 
development of potent teixobactins due to several 
synthetic challenges such as (1) it is not commercially 
available, (2) it requires a multistep synthesis (7 steps, 
17% yield)8, (3) a suitably protected L-allo-
enduracididine is difficult to incorporate into 
teixobactin and (4) it requires long and multiple 
couplings (16-30 hours).8 9 Due to all of these 
challenges, the synthesis of teixobactin is laborious and 
low yielding (3.3%).  
 
The synthesis of all our analogues involved loading 
Fmoc-alanine on the 2-chlorotritylchloride resin, 
followed by amide coupling with Alloc-NH-D-Thr-OH,  
 
 
Figure 2. Structure of teixobactin analogues 1-15 synthesised with the replaced amino acids highlighted in red. 
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resin esterification with 10 eq. Fmoc-Ile-OH, and 
adding 10 eq. DIC and 5 mol% DMAP for 2h. The next 
amino acid (AA) was then coupled using 4 eq. AA with 
4 eq. HATU/8 eq. DIPEA in DMF for 1h followed by 
Fmoc deprotection and trityl protection. Next, the N-
terminal alloc protecting group was removed using 
Pd(PPh3)4 and phenylsilane (Figure 3). All other amino 
acids were coupled using 4 eq. AA with 4 eq. 
DIC/Oxyma using an automated microwave peptide 
synthesiser (coupling time of 10 min each). Fmoc 
deprotection was performed using 20% piperidine in 
DMF (Figure 3, page S3). Cyclisation was performed 
using 1 eq. HATU and 10 eq. DIPEA and was found to 
be complete within 30 min with complete conversion of 
the linear product into its cyclised counterpart (pages 
S5-S32). Yields after HPLC purification were found to 
be 10-24% (Table S1). We have identified a unique 
design in which the introduction of hydrophobic 
residues such as leucine at position 10 (Figure 1) has 
several advantages over the lengthy low-yielding (3.3%) 
synthesis of teixobactin, including overall yields of up 
to 24%, faster automated syntheses, and use of 
commercially available building blocks. 
 
Figure 3. Synthesis of Leu10-teixobactin starting from 2-Chlorotritylchloride 
resin: a. 4 eq. Fmoc-Ala-OH/8 eq. DIPEA in DCM, 3h.   b. 20% piperidine in 
DMF followed by 3 eq. AllocHN-D-Thr-OH, 3 eq. HATU/6 eq. DIPEA, 1.5h   
c. 10 eq. Fmoc-Ile-OH, 10 eq. DIC, 5 mol% DMAP in DCM, 2h followed by 
capping with Ac2O/DIPEA 10% in DMF, 20% piperidine in DMF   d. 4 eq. 
Fmoc-Leu-OH, 4 eq. HATU/8 eq. DIPEA in DMF, 1h followed by 20% 
piperidine in DMF   e. 10 eq. Trt-Cl, 15% Et3N in DCM, 1h.  f. 0.2 eq. 
[Pd(PPh3)4]0 + 24 eq. PhSiH3 in dry DCM, 1x20 min, 1x45 min.   g. 4 eq. 
Fmoc/Boc-AA(PG)-OH (AA = amino acid, PG = protecting group), 4 eq. 
DIC/Oxyma (µwave, 10 min) followed by 20% piperidine in DMF (3 min, 10 
min).   h. TFA:TIS:DCM = 2:5:93, 1h.  i. 1 eq. HATU/10 eq. DIPEA in DMF, 
30 min.   j.  TFA:TIS:H2O = 95:2.5:2.5, 1h.  
Teixobactin and its active analogues such as Arg10-
teixobactin and Lys10-teixobactin contain two positive 
charges. However, the analogues 1, 8-15 contain only 
one positive charge and were therefore found to be more 
hydrophobic than the analogues 2-7. All the compounds 
were found to be completely soluble in DMSO. 
Therefore, stock solutions of these compounds were 
prepared in DMSO for MIC testing. Upon dilution in 
the Mueller Hinton broth (Oxoid) culture media in 
which bacteria were grown (concentration ~256 
µg/mL), no turbidity or precipitation was observed 
indicating that the compounds were soluble in the 
culture media. 
 
Antibacterial studies. Analogues of teixobactin 
derived through an alanine scanning of teixobactin 
reveal that residues N-Me-Phe1, Ile2 D-allo-Ile5, L-Ile6 
and Ser7 are important for antibacterial activity and their 
replacement by L-Ala or D-Ala results in decrease in 
biological activity (Table 1). Interestingly, replacement 
of L-Ser3 and D-Gln4 by L-Ala and D-Ala has no effect 
on antibacterial activity. Thus, the two residues L-Ser3 
& D-Gln4 are ideal candidates for replacement in the 
case of teixobactin due to their more facile synthesis 
and minimal impact on biological activity. It has been 
suggested that replacement of any of the residues in the 
core ring structure of teixobactin negates all biological 
activity of the molecule.12 In our case, however, the 
most interesting result was obtained through the 
replacement of L-Arg10 by L-Ala (8). 
 
The design and syntheses of potent teixobactin 
analogues published in the literature has thus far been 
limited to the substitution of L-allo-enduracididine with 
amino acids such as Arg,10 11 Lys12 and Orn9, all of 
which possess a cationic side chain. A positive charge is 
a common structural characteristic of depsipeptides 
which bind to lipid II4. L-allo-enduracididine is thus 
reported to be important for potent antibacterial activity 
of teixobactin.8 Therefore, it was expected that 
replacement of this residue with alanine, which is non-
polar and uncharged, would completely abolish the 
biological activity of the molecule. Contrary to this, we 
observed that Ala10-teixobactin was highly active 
against MRSA (Table 1) with an MIC of 1-2 µg/mL. 
 
A plausible explanation could be that Ala10-teixobactin 
binds to the pyrophosphate motif of lipid II using the 
amide backbone in a similar way to that proposed for 
the binding of nisin.19 Superior results were obtained 
with Ile10-teixobactin (12) and Leu10-teixobactin (13), 
which consistently gave identical MIC values of 0.25 
µg/ml as compared to the teixobactin against MRSA 
(Table 1). Leu has a very similar hydrocarbon 
framework to L-allo-enduracididine (Figure 1), 
followed very closely by Ile, which could explain the 
identical MIC value of these analogues (12 & 13) to 
teixobactin (17) against MRSA. In order to determine 
the effect of serum on antibacterial activity, the MIC of 
compounds 12 and 13 were measured in presence of 
10% human serum (Page S53). In both cases no change 
was observed in the MIC (Table 1) indicating that 10% 
human serum has no effect on the antibacterial activity. 
 
The fact that a cationic residue at position 10 is not 
essential for antibacterial activity represents a 
significant breakthrough in teixobactin research given  
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Compound Name MIC* 
(µg/mL)         
1 Ac-D-Ala1-Arg10-
texiobactin 
>128 
2 Ala2-Arg10-teixobactin >128 
3 Ala3-Arg10-teixobactin 1-2 
4 D-Ala4-Arg10-teixobactin 2-4 
5 D-Ala5-Arg10-teixobactin 64-128 
6 Ala6-Arg10-teixobactin >128 
7 Ala7-Arg10-teixobactin 16-32 
8 Ala10-teixobactin 1-2 
9 D-Ala10-teixobactin 32 
10 Gly10-teixobactin 2 
11 Val10-teixobactin 0.5 
12 Ile10-teixobactin 0.25 
12a Ile10-teixobactin + 10% 
human seruma 
0.25 
13 Leu10-teixobactin 0.25 
13a Leu10-teixobactin + 10% 
human seruma 
0.25 
14 Ser10-teixobactin 16 
15 Phe10-teixobactin 2 
16 Arg10-teixobactin 2 
17 Teixobactin 0.25 
18 Vancomycin 2 
Table 1. List of teixobactin analogues (1-15). MIC: Minimum Inhibitory 
Concentration. *MRSA ATCC 33591 used. Culture Media: Mueller Hinton 
Broth (Oxoid) a 10% volume with human serum (SIGMA, H4522) 
the earlier stated importance of the L-allo-
enduracididine amino acid in the total synthesis of 
teixobactin.8 Our design has considerably improved not 
only the antibacterial activity of teixobactin analogues 
but also the ease of synthesis. Our findings are of 
particular importance as MRSA is responsible for many 
infections worldwide.20 
 
D-Ala10-teixobactin shows 16-times lower antibacterial 
activity than Arg10-teixobactin which would be 
expected, as inversion of configuration of even a single 
amino acid in the core ring structure can significantly 
lower the MIC value of a  teixobactin analogue.12 
Surprisingly, Gly10-teixobactin (10) shows identical 
activity to Arg10-teixobactin (16) showing that complete 
removal of the chiral center at position 10 is tolerated 
provided the configuration of the remaining residues is 
intact. Val10-teixobactin (11) shows 4-times better 
antibacterial activity than Arg10-teixobactin but Ser10-
teixobactin (14) shows 8-times lower activity, indicating 
that Ser at position 10 probably interferes with 
hydrogen bonding between the core ring structure of 
teixobactin and lipid II. Phe10-teixobactin (15) gave an 
MIC of 2 µg/mL against MRSA indicating that an 
aromatic amino acid such as Phenylalanine at position 
10 is also tolerated. Overall, from our work it appears 
that the claimed importance of a charged residue at 
position 10 in the form of an amine or guanidine group 
in texiobactin has been overstated in the literature given 
that the most potent analogues obtained thus far are the 
Leu10-teixobactin and Ile10-teixobactin both of which 
are non-polar and non-charged. This unexpected result 
facilitates the development of several highly potent 
teixobactin analogues against a broader panel of MRSA, 
MSSA and Enterococcus faecalis (VRE) including 
Mycobacterium smegmatis (Table 2) but with 
significantly higher yields compared to teixobactin. 
Although analogues of teixobactin with improved yields 
have been synthesised previously10-16, none possess 
comparable activity to teixobactin and therefore the 
yields obtained for Ile10-teixobactin and Leu10- 
teixobactin (Table S1, S4, 10-20%) cannot be compared 
to those of the other less potent analogues of teixobactin 
described in literature.10-16 Based on the initial MIC 
results (Table 1), we identified Ala10-teixobactin (8), 
Val10-teixobactin (11), Ile10-teixobactin (12) and Leu10-
teixobactin (13) as our lead compounds. These 
compounds along with Arg10-teixobactin (16), and 
vancomycin/daptomycin as controls, were tested against 
an extended panel of Gram positive bacteria (Table 2) to 
provide a more comprehensive overview of the 
biological activity of these molecules. A significant 
difference in MIC was observed in the presence and 
absence of polysorbate 80 (Table S4, S54).2 Leu10-
teixobactin (13) showed potent activity against M. 
 
Table 2: MIC and MBC (in µg/mL) of the teixobactin analogues 8, 11-13, 16 and daptomycin control against an extended panel of Gram positive bacteria. 
Strain information: MRSA 1: MRSA ATCC 700699, MRSA 2: MRSA DR 42412 (sputum), MRSA 3: MRSA DM21455 (eye). MRSA 2 and MRSA 3 are 
clinical isolates. Staphylococcus aureus ATCC 29213, Enterococcus faecalis (VRE 1:  VRE ATCC 700802, VRE 2: VRE ATCC 29212). M. smegmatis ATCC 
607. Culture Media: Mueller Hinton Broth. 
Strain        Compound  
   
 (8)  (11)  (12)  (13)  (16) Vancomycin Daptomycin 
MRSA 1 
MIC 4 1 0.25 0.25 1 2 0.5 
MBC 16 4 1 2 2 - - 
MRSA 2 
MIC 1 0.5 ≤ 0.0625 ≤ 0.0625 0.125 2 0.5 
MBC 4 4 ≤ 0.0625 ≤ 0.0625 0.5 - - 
MRSA 3  
MIC 1 0.25 ≤ 0.0625 ≤ 0.0625 0.5 2 0.5 
MBC 2 2 0.125 ≤ 0.0625 1 - - 
Staphylococcus 
aureus 
MIC 1 0.25 ≤ 0.0625 ≤ 0.0625 0.25 4 0.25 
MBC 2 1 0.125 0.125 1 -  
VRE 1 MIC 4 0.5 ≤ 0.0625 0.25 2 >4 0.5 
VRE 2 MIC 4 0.5 ≤ 0.0625 0.25 2 >4 0.5 
M. smegmatis MIC 1-2 - 0.5 1 1-2 >64 - 
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Peptide, µg/mL
Leu10-teixobactin
Ile10-teixobactin
smegmatis (MIC ~ 1 µg/mL). Ala10-teixobactin (8) and 
Arg10-teixobactin (16) showed comparable activity 
against M. smegmatis with MICs in the range of 1-2 
µg/mL. In general, the MBCs of all compounds were 
found to be 2-4 times the MIC value. Ile10-teixobactin 
(12) and Leu10-teixobactin (13) were found to be the 
most potent compounds showing MICs ≤ 0.25 µg/mL in 
all strains. Ile10-teixobactin (12) in particular was found 
to be highly active against both VRE strains with MICs 
≤ 0.0625 µg/mL and also an MIC 0.5 of µg/mL against 
M. smegmatis. We thus report, for the first time, two 
analogues of teixobactin showing highly potent 
antibacterial activity against a broader panel of resistant 
Gram positive bacteria. This is a very significant 
advancement in terms of teixobactin research and 
allows for the synthesis of a library of teixobactin 
derivatives based on Ile10-teixobactin and Leu10-
teixobactin which can be simpler, highly potent and 
significantly more cost effective than the synthesis of 
teixobactin.  
 
Time dependent killing of bacteria using teixobactin 
analogues 12 and 13. Early stage time-kill kinetics for 
Ile10-teixobactin (12) and Leu10-teixobacitn (13) against 
MRSA ATCC 21455 using vancomycin as a control 
were carried out as described (Page S52).2 At 0.5 µg/ml, 
both Ile10-teixobactin (12) and Leu10-teixobactin (13) 
were found to elicit complete bactericidal activity 
within 8 h whereas substantial growth was observed in 
the presence of vancomycin (0.5 µg/ml, Figure 4A). 
The concentration of vancomycin needs to be increased 
to 8 µg/ml in order to have similar effects as the 
teixobactin analogues 12 & 13 (Figure 4B). 
 
Toxicity studies and haemolysis assay. The analogues 
Ala10-teixobactin (8), Val10-texiobactin (11) and Leu10-
teixobactin (13) were tested on HeLa cell cultures and 
no significant toxicity was observed (relative survival 
90-100%) up to a concentration of 100 µM (Figure S79) 
which is well above the MIC values (0.2-0.8 µM, 125-
500 times). Additionally, a haemolytic assay using 
Leu10-teixobactin and Ile10-teixobactin against rabbit 
erythrocytes using Melittin as a control (Figure 5) 
indicated that peptides Leu10-teixobactin (13) and Ile10-
teixobactin (12) did not show any discernible 
haemolytic activity, even at concentrations that exceed 
>500x the mean MIC values whereas substantial 
haemolytic activity was observed for melittin (Figure 
5). These results establish the non-haemolytic properties 
of the designed teixobactin analogues.  
 
Figure 4. A. Time-kill kinetics of teixobactin analogues 12 & 13 with a 
comparative antibiotic (vancomycin) against MRSA 21455. The 
concentration of teixobactin analogues and vancomycin are maintained at 0.5 
µg/ml.  B. Time-kill kinetics of teixobactin analogues with vancomycin 
against MRSA 21455 strains at elevated concentrations of the antibiotics. At 8 
µg/ml concentration the kill kinetics profiles are similar for vancomycin & 
teixobactin analogues 12 & 13. The horizontal dotted line represents the limit 
of detection. 
Figure 5. Hemolytic activity of teixobactin analogues 12 and 13 for rabbit 
erythrocytes. The blood cells were exposed to various concentrations of 
peptides for 1 h and the release of haemoglobin was determined 
spectrophotometrically. Each value represents an average of triplicate 
experiments.  
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Lipid II binding assay. To better understand the potent 
antibacterial activity of Ala10-teixobactin we have 
performed the lipid II TLC binding assay as reported 
earlier for teixobactin.2 Teixobactin and Arg10-
teixobactin bind to lipid II in a 2:1 ratio resulting in the 
complete disappearance of the lipid II spot on TLC 
(Figure S76). Although Ala10-teixobactin also shows 
binding with lipid II in a 2:1 ratio, a small amount of 
lipid II was still visible on TLC. The lipid II spot, 
however, completely disappears by increasing the 
concentration of Ala10-teixobactin (Figure S77). TLC 
binding studies with Leu10-teixobactin also showed 
complete disappearance of the lipid II spot when a ratio 
of 2:1 was used (Figure S78). It is very interesting that 
Ala10-teixobactin and Leu10-teixobactin were able to 
bind to lipid II without having a cationic amino acid 
residue like L-allo-enduracididine/arginine off the 
cyclic peptide ring. 
 
Geranyl Pyrophosphate (lipid II mimic) binding 
studies. In order to evaluate target binding, we have 
performed the lipid II TLC binding assay2 with Ala10-
teixobactin. This assay provides qualitative binding data 
of Ala10-teixobactin with lipid II. Although the 
technique is fast and effective, the results obtained via 
this method do not necessarily reflect whole cell 
activities. This has been reported previously by us 
where both D and L derivatives of teixobactin were 
found to bind to lipid II but only the former was 
biologically active.13 Therefore, in order better 
understand the target binding of teixobactin analogues 
in a quantitative manner, extensive NMR studies 
(Figure 6) on Ala10-teixobactin and geranyl 
pyrophosphate were performed. Geranyl pyrophosphate 
possesses a pyrophosphate and isoprenyl chain similar 
to lipid II making it suitable for solution phase NMR 
studies.  
Both TLC (Figure S77) and NMR (Figure 6, Table 3) 
suggest a 2:1 binding between Ala10-teixobactin and 
geranyl pyrophosphate. When titrating geranyl 
pyrophosphate into Ala10-teixobactin certain residues 
such as Ser7 were found to bind with classic Michaelis-
Menton binding kinetics (Figure 6B). However, some 
isotherms exhibited a sigmoidal shape (Figure 6A). This 
can occur due to intermediate exchange on the NMR 
time-scale, and therefore cooperative binding is not an 
obvious choice. However, given our initial TLC data 
which shows a binding of 2:1 we have fitted the 
sigmoidal data using the Hill coefficient. It was found 
that all N-terminal residues weakly bound (KD ~0.5mM) 
geranyl pyrophosphate in a highly cooperative (Hill 
coefficient ~2) manner, whereas ring-proximal residues 
bound significantly tighter but less cooperatively. 
Tightest binding was observed for Ser7 (KD ~125μM), 
which in a recently published teixobactin X-ray 
structure12 points its hydroxyl directly towards a bound 
anion. Analysing the overall binding using PCA (Figure 
6C), which removes any influence of intermediate 
exchange from the isotherms,21 gave a net KD of ~138 
μM. 
 
In order to determine if teixobactin aggregates in the 
presence of geranyl pyrophosphate 1H DOSY (diffusion 
ordered spectroscopy) spectra were recorded at each 
titration point and the diffusion coefficients calculated 
for both geranyl pyrophosphate and teixobactin (Figure 
7). Over the course of the titration the diffusion 
coefficient obtained from Ala10-teixobactin remained 
constant, indicating no aggregation occurred. The 
diffusion coefficient observed for geranyl 
pyrophosphate increased slightly over the course of the 
titration, indicating that it may have adopted a more 
compact structure upon association with the teixobactin. 
 
Figure 6. Selected binding isotherms obtained from titrations of geranyl pyrophosphate into Ala10-teixobactin demonstrating residue-specific binding behavior 
with cooperative characteristics. Error bars show RMS of function fit. PC: Principal Component 
  
A B C
8 
Table 3. Dissociation constants between Ala10-teixobactin and geranyl 
pyrophosphate at residue resolution, as determined by NMR titration. A blank 
Hill coefficient indicates Michaelis-Menton binding kinetics was sufficient to 
satisfactorily describe the titration data. 
 
Figure 7. Graph of Diffusion co-efficient vs concentration of geranyl 
pyrophosphate indicating teixobactin does not aggregate when exposed to 
increasing geranyl pyrophosphate concentrations. Error bars indicate standard 
deviation of the fitting function. 
 
Antagonization assay. In order to further prove a lipid 
II mediated mode of action, an antagonization assay was 
performed using Leu10-teixobactin (13) with lipid II as 
described in literature.2 The ratios of Leu10-teixobactin 
to lipid II tested were 1:0.5, 1:1, 1:2 and 1:5 and growth 
was observed. These results are consistent with the 2:1 
binding ratio observed using the TLC assay. (Table S3). 
However in case of Leu10-teixobactin (control), no 
growth was observed.  
 
Structural studies using NMR. NMR analysis of 
teixobactin analogues (Figure 8) reveals common 
structural characteristics between those analogues which 
retain some residual antibacterial activity. Ala10-
teixobactin was chosen for NMR studies as it provides 
the most direct comparison with other analogues. All 
analogues retain most of the NOEs observed in the 
Arg10-teixobactin, despite some differences in amide 
chemical shift (Figure 8A). From figure 8B and 8C it 
can be observed that α proton chemical shifts show little 
variation between analogues at both termini: N-terminal 
similarities are likely due to these residues existing in a 
random coil environment; C-terminal similarities are 
likely due to the restraints placed upon these residues by 
the ring structure. Amide chemical shifts are more 
variable, particularly for residues 7 and 8, in which the 
chemical shift of these protons is ~1 ppm downfield in 
Ala10-teixobactin (8). This is likely due to the loss of the 
guanidinium group, and suggests proximity between 
these residues and Arg10. The N-terminus again shows 
little variation, characteristic of a random coil. The 
mutated residue chemical shifts were excluded from the 
statistics. Figure 8D shows that in all three mutants 
Ala3-Arg10-teixobactin (3), Ala4-Arg10-teixobactin (4) 
and Ala10-teixobactin (8) the N-termini were 
unstructured, but were showing evidence of structure 
starting approximately from residue 5, where in all 
cases the RMSD had dropped by ~50% from that 
observed at their termini. The RMSDs observed at the C 
termini are low, as this area is highly constrained in 
structure by the ring. 
 
Conclusion  
In conclusion, we have described a unique design and 
rapid synthesis of several highly potent teixobactin 
analogues by replacing the synthetically challenging 
amino acid L-allo-enduracididine with the 
commercially available non-polar residues such as 
leucine (13) and isoleucine (12). The teixobactin 
analogues from this work have shown highly potent 
antibacterial activity against a broad panel of MRSA, 
MSSA and VRE, despite their simpler design. Early 
stage kill kinetics data suggests Leu10-teixobactin and 
Ile10-teixobactin to be superior to vancomycin against 
MRSA. An antagonization assay suggests a lipid II 
mediated mode of action for Leu10-teixobactin. Most 
importantly, contrary to the current understanding we 
have demonstrated that cationic amino acids such as L-
allo-enduracididine, arginine or lysine at position 10 are 
not essential for target (lipid II) binding and 
antibacterial activity. This surprising finding opens the 
door to the design and syntheses of several highly 
simplified potent teixobactin analogues and challenges 
many of the current assumptions about the mechanism 
of action of teixobactin. Our design of highly potent 
teixobactin analogues has several advantages such as 
improved yields ~10-20%, ease of synthesis (including 
10 min µwave assisted coupling steps and a 30 min 
cyclisation step) and uses commercial available building 
blocks.  
Entry KD (μM) Hill coefficient 
1  Me-D-Phe Hα n.d. n.d. 
2  Ile Hα 348 ± 18 2.1 
3  Ser Hα 503 ± 8 2.0 
4  D-Gln Hα 507 ± 2 2.2 
5  D-Ile Hα 483 ± 4 1.7 
6  Ile Hα n.d. n.d. 
7  Ser Hα 125 ± 3  
8  D-Thr Hα 204 ± 3  
9  Ala Hα 394 ± 4 2.1 
10 Ala Hα 314 ± 3  
11 Ile Hα 391 ± 4 1.5 
Net 138 ± 5  
9 
Figure 8. A. Overlay of the amide fingerprint regions of the 1H-1H NOESY spectra of wild type (Arg10-teixobactin) and active teixobactin analogues. B and C. 
Chemical shift data obtained from α (B) and amide (C) protons. D. Statistics of structures calculated using the NOEs obtained from panel A. For clarity, the 
DMSO (~3.3 ppm) and residual water (~2.5 ppm) signals have been obscured with grey boxes. Data show the average RMSD of each atom in the residue from 
all 20 members of the ensemble. Error bars are standard deviation in the RMSDs of each residue's atoms. Standard deviations were calculated including the 
chemical shifts for 15.11 Ensembles of 20 structures generated by Cyana 2.122 and refined in Gromacs23. Error bars indicate standard deviation amongst all the 
atoms of that residue. Spectra were recorded on 1 mM teixobactin samples dissolved in DMSO-d6 on a 500 MHz spectrometer at 300 K. Legends for Figure 5B 
and 5C are the same, and are shown in panel C 
NMR studies reveal that the analogues Ala3-Arg10-
teixobactin (3), Ala4-Arg10-teixobactin (4) and Ala10-
teixobactin (8) are more unstructured towards the N-
termini but highly structured towards the C termini due 
to the close-by ring. We have performed qualitative 
lipid II binding experiments and measured the binding 
affinities of individual amino acid residues of Ala10-
teixobactin and geranyl pyrophosphate (lipid II mimic) 
by NMR to understand the role of amino acid residues 
in binding. Ser7 was found to have the tightest binding 
with an experimental KD of 125 µM. 
 
To the best of our knowledge, Ile10-teixobactin (12) and 
Leu10-teixobactin (13) are the only reported teixobactin 
analogues which have shown superior potency against 
resistant Gram positive bacteria. The results from this 
work represent a significant advancement in our current 
understanding of the residues critical to the biological 
activity of teixobactin and associated analogues. We 
anticipate that our design and relatively rapid synthesis 
will help overcome current challenges in the field. As it 
stands, our work herein provides ready access to highly 
potent teixobactin analogues and will enable the 
development of teixobactin analogues with drug like 
properties against resistant bacterial strains. The 
findings presented in this work have broad implications 
and are expected to facilitate the development of 
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peptide based antibiotics for combatting the serious 
global challenges posed by AMR. 
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